Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes

ConclusionsAs part of an integrative risk assessment, this study demonstrated no clinically relevant corrected QT prolongation with vericiguat 10 mg once daily at steady state.Clinical Trial RegistrationClinicalTrials.gov number, NCT03504982.Graphical Abstract
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research